1-Cyclopropyl-6,8-difluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

This is the chemical structure analysis of 1-cyclopropyl-6,8-difluoro-7- [ (4aS, 7aS) -octahydro-6H-pyrrolio [3,4-b] pyridine-6-yl] -4-oxo-1,4-dihydroquinoline-3-carboxylic acid. Its structure is first in the quinoline parent nucleus, cyclopropyl is added at the 1st position, fluorine atoms at the 6th and 8th positions, carbonyl at the 4th position, and carboxyl at the 3rd position. In particular, the structure of the 7-position connected [ (4aS, 7aS) -octahydro-6H-pyrrolido [3,4-b] pyridine-6-yl] is complex. The pyridine ring undergoes the octahydro process and is formed according to the specific configuration of (4aS, 7aS). The parallel ring of pyrrolido [3,4-b] allows the 6-position to be connected to the 7-position quinoline. This structure makes the compound have unique chemical activity and spatial configuration, and may have special effects in fields such as medicinal chemistry. Due to this structural feature, it may affect its fit and interaction with biological targets.

1-Cyclopropyl-6,8-difluoro-7- [ (4aS, 7aS) -octahydro-6H-pyrrolido [3,4-b] pyridine-6-yl] -4-oxo-1,4-dihydroquinoline-3-carboxylic acid, this is the name of the chemical substance. Its main use is more common in the field of medicine.
This compound is of great significance in the development of antibacterial drugs. Its unique chemical structure gives it the ability to bind to specific bacterial targets, which in turn demonstrates antibacterial activity. It can target a variety of bacteria, effectively inhibit their growth and reproduction, and has a certain effect on Gram-positive bacteria and Gram-negative bacteria. It has potential efficacy in the treatment of bacterial-induced infectious diseases.
Also used in scientific research. Through in-depth investigation of its chemical properties and pharmacological properties, researchers can better understand the mechanism of action of antibacterial drugs, providing key theoretical support and practical experience for the development of more efficient and safe new antibacterial drugs. By studying its reaction and activity changes under different conditions, it helps to optimize drug design, improve drug efficacy, and reduce adverse reactions.
Furthermore, in the field of pharmaceutical chemical synthesis, this compound is an important intermediate. With its structural characteristics, a variety of structural analogs can be further derived through a series of chemical reactions, expanding the medicinal chemistry space, and providing rich materials and possible paths for the creation of new drugs. In the synthesis of many new antimicrobial drugs, it is often used as the starting material or key structural fragments, and ingeniously chemically modified to obtain drug molecules with better properties.

1-Cyclopropyl-6,8-difluoro-7- [ (4aS, 7aS) -octahydro-6H-pyrroso [3,4-b] pyridine-6-yl] -4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which is the name of the chemical substance. The preparation method of the ancient method may be:
First take a specific quinoline starting material, which needs to have a specific structure in order to lay the foundation for the subsequent reaction. From the ancient perspective, the selection of starting materials is extremely cautious, and it must be pure and accurate in structure.
At the beginning of the reaction, cyclopropyl is often introduced. This process requires a specific reaction environment, such as in a suitable solvent, or supplemented by some specific catalyst. The choice of solvent depends on whether the reaction can proceed smoothly, and the amount and activity of the catalyst also have a profound impact on the reaction rate and product purity.
Then, the fluorine atoms at positions 6 and 8 are introduced into the step. This step requires delicate control of the reaction conditions. Temperature and reaction time are key factors. Too high or too low temperature may cause the reaction to deviate from expectations, or the product is impure, or the yield is low. And the reagents with fluorine atoms are introduced, and their activity and reactivity must meet specific requirements.
As for the construction of the 7-position [ (4aS, 7aS) -octahydro-6H-pyrrolido [3,4-b] pyridine-6-yl], the process is even more complicated. It needs to go through multiple steps of reaction, or first construct the parent nuclear structure of pyrrolido-pyridine, and then modify it through hydrogenation and other steps to obtain the desired specific configuration. Each step of reaction needs to be carefully regulated to ensure the accuracy of the product configuration.
Finally, the structure of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid is formed. This step may involve oxidation, carboxylation and other reactions, and the connection between each reaction must also be appropriate, otherwise it is easy to cause side reactions and the quality of the product is difficult to control.
The preparation of ancient, although the technical means are not as rich as today, but with the careful study and control of each step, this compound can also be obtained. During the preparation process, the emphasis on raw materials, reaction conditions, and the connection of each step is really the essence of the preparation of this compound by ancient methods.

1-Cyclopropyl-6,8-difluoro-7- [ (4aS, 7aS) -octahydro-6H-pyrroso [3,4-b] pyridine-6-yl] -4-oxo-1,4-dihydroquinoline-3-carboxylic acid, the drug products related to the substances referred to by this chemical name are mostly quinolone antibacterial drugs. The following is the introduction of related drug products:
Levofloxacin is a commonly used quinolone antibacterial drug. It has good antibacterial activity against Gram-positive and negative bacteria. It can hinder the activity of bacterial DNA rotatase (bacterial topoisomerase II) and inhibit bacterial DNA replication, so as to achieve antibacterial effect. It is widely used in the treatment of respiratory tract infections, such as pneumonia, bronchitis, urinary system infections, intestinal infections and other diseases. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and is well absorbed orally and widely distributed in the body.
Ciprofloxacin is also an important member of the quinolone family. It is particularly effective against Gram-negative bacteria such as Pseudomonas aeruginosa. It is often used to treat urinary and reproductive system infections, respiratory tract infections, gastrointestinal tract infections, bone and joint infections caused by sensitive bacteria. By inhibiting bacterial DNA synthesis and replication, bacteria die. It has high antibacterial activity and is also effective against a variety of drug-resistant bacteria.
Moxifloxacin, the antibacterial spectrum is further expanded, and it has antibacterial activity against Gram-positive bacteria, negative bacteria, anaerobic bacteria and atypical pathogens such as mycoplasma and chlamydia. It is widely used in the treatment of community-acquired pneumonia, and can also be used for skin and soft tissue infections. Its pharmacokinetic properties are excellent, tissue penetration is good, and it can reach effective antibacterial concentrations in the body.
Although such drugs have significant antibacterial effects, they should be used with caution. Because it may cause adverse reactions such as gastrointestinal discomfort and central nervous system symptoms, and long-term or improper use is prone to bacterial resistance. Therefore, in clinical application, it is necessary to choose and standardize the use according to the type of pathogenic bacteria and drug susceptibility results to ensure the efficacy and drug safety.

1-Cyclopropyl-6,8-difluoro-7- [ (4aS, 7aS) -octahydro-6H-pyrrolo [3,4-b] pyridine-6-yl] -4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which is an important compound in the field of chemistry, or has outstanding performance in the field of pharmaceutical research and development.
Looking at its market prospects, from the past development trend of the pharmaceutical industry, compounds with specific structures and activities are often the key to research and development. This compound has a unique structure or endows it with novel biological activities, or can play a role in specific disease targets, thus emerging in the fields of anti-bacteria and anti-tumor.
In today's pharmaceutical market, there is a voracious demand for high-efficiency, low-toxicity and specific drugs. If this compound can exhibit good pharmacological properties through in-depth research and development, its market potential is immeasurable. For example, in the field of antimicrobial drugs, the problem of drug-resistant bacteria is becoming increasingly serious, and new antimicrobial compounds will surely gain a large market share if they can be effectively dealt with.
Furthermore, with the continuous improvement of drug development technology, such as computer-aided drug design, high-throughput screening and other means, the research and development process of such compounds may be accelerated. If the research and development goes well, after being introduced to the market, it is expected to gain a share of the highly competitive pharmaceutical market, bringing rich returns to the company and good news to patients.
However, its research and development path is also full of thorns. Drug research and development requires multiple rounds of rigorous trials, from cell experiments, animal experiments to human clinical trials. Failure in any link may lead to premature research and development. And the market competition is intense, and drugs of the same or similar mechanism of action are also competing for research and development. This compound needs to stand out in terms of efficacy, safety, cost, etc., in order to be recognized by the market.